Volgen
Samir Kulkarni
Samir Kulkarni
Massachusetts Institute of Technology
Geverifieerd e-mailadres voor tudelft.nl
Titel
Geciteerd door
Geciteerd door
Jaar
Crystal nucleation kinetics from induction times and metastable zone widths
SA Kulkarni, SS Kadam, H Meekes, AI Stankiewicz, JH ter Horst
Crystal growth & design 13 (6), 2435-2440, 2013
2192013
A new view on the metastable zone width during cooling crystallization
SS Kadam, SA Kulkarni, RC Ribera, AI Stankiewicz, JH ter Horst, ...
Chemical engineering science 72, 10-19, 2012
1712012
Isonicotinamide self-association: the link between solvent and polymorph nucleation
SA Kulkarni, ES McGarrity, H Meekes, JH ter Horst
Chemical communications 48 (41), 4983-4985, 2012
1442012
Template-induced nucleation of isonicotinamide polymorphs
A Caridi, SA Kulkarni, G Di Profio, E Curcio, JH Ter Horst
Crystal growth & design 14 (3), 1135-1141, 2014
462014
Polymorphism control through a single nucleation event
SA Kulkarni, H Meekes, JH Ter Horst
Crystal growth & design 14 (3), 1493-1499, 2014
412014
The use of cooling crystallization in an ionic liquid system for the purification of pharmaceuticals
CC Weber, SA Kulkarni, AJ Kunov-Kruse, RD Rogers, AS Myerson
Crystal Growth & Design 15 (10), 4946-4951, 2015
402015
Self-association during heterogeneous nucleation onto well-defined templates
SA Kulkarni, CC Weber, AS Myerson, JH Ter Horst
Langmuir 30 (41), 12368-12375, 2014
362014
Development of the Commercial Manufacturing Process for Nirmatrelvir in 17 Months
C Allais, CG Connor, NM Do, S Kulkarni, JW Lee, T Lee, E McInturff, ...
ACS Central Science 9 (5), 849-857, 2023
162023
Understanding polymorph selection of sulfamerazine in solution
C Liu, F Cao, SA Kulkarni, GPF Wood, EE Santiso
Crystal Growth & Design 19 (12), 6925-6934, 2019
122019
Early clinical development of lufotrelvir as a potential therapy for COVID-19
C Allais, D Bernhardson, AR Brown, GM Chinigo, JN Desrosiers, ...
Organic process research & development 27 (12), 2223-2239, 2023
102023
Cross-pharma collaboration for the development of a simulation tool for the model-based digital design of pharmaceutical crystallization processes (CrySiV)
B Szilagyi, WL Wu, A Eren, J Mackey, S Kshirsagar, E Szilagyi, ...
Crystal Growth & Design 21 (11), 6448-6464, 2021
92021
Two-Stage Crystallizer Design for High Loading of Poorly Water-Soluble Pharmaceuticals in Porous Silica Matrices
L Dwyer, S Kulkarni, L Ruelas, A Myerson
Crystals 7 (5), 131, 2017
72017
Methods for nano-crystals preparation
SA Kulkarni, AS Myerson
Engineering Crystallography: From Molecule to Crystal to Functional Form …, 2017
72017
Reversible control of solubility using functionalized nanoparticles
SA Kulkarni, AS Myerson
Chemical communications 53 (8), 1429-1432, 2017
72017
Synthesis of Nirmatrelvir: Design and Optimization of an Efficient Telescoped Amidation–Dehydration Sequence
RF Algera, AF Baldwin, P Bowles, HJ Clarke, CG Connor, EM Cordi, ...
Organic Process Research & Development 27 (12), 2250-2259, 2023
52023
Methods for the purification of L-glufosinate
SC Fields, MR Oberholzer, BM Green, S Kulkarni, J Nelson, P Andres
US Patent 11,634,442, 2023
22023
Streamlined Synthesis of a Bicyclic Amine Moiety Using an Enzymatic Amidation and Identification of a Novel Solid Form
MS Brown, MA Caporello, AE Goetz, AM Johnson, KN Jones, KM Knopf, ...
Organic Process Research & Development 25 (6), 1419-1430, 2021
22021
Validation of the single nucleus mechanism by polymorphism
S Kulkarni, SS Kadam, AI Stankiewicz, H Meekes, JH ter Horst
BIWIC2011, 75-80, 2011
12011
Compounds and methods for the treatment of COVID-19
RS Kania, P Bezawada, EL Hawking, R Jaini, S Kulkarni, MNOB Laramy, ...
US Patent 11,926,642, 2024
2024
Methods for the purification of L-glufosinate
SC Fields, MR Oberholzer, BM Green, S Kulkarni, J Nelson, P Andres
US Patent 11,897,909, 2024
2024
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20